243 results about "Vasodilation" patented technology

Embodiments of the invention include a method and a device for increasing vasodilatation and / or controlling the temperature of a mammal by applying a desired vacuum pressure to the skin of the extremity of a mammal. In some cases it is also desirable to provide heat to regions of the extremity of the mammal to further dilate the veins or arteries in the patient. In some cases it is also desirable to apply a contact pressure to regions of the extremity of the mammal to improve perfusion of these regions. In one embodiment, the device includes a device that is adapted to rigidly enclose a portion of an extremity of the mammal therein so that a sub-atmospheric pressure can be applied to the mammal's extremity, which is further discussed below.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, perdiodontitis, and oral malodor while also promoting general oral hygiene.

Metal carbonyls are used to deliver CO having biological activity, for example vasodilatation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g. Fe and Ru. The carbonyl preferably has one or more ligands other than CO, such as amino acids, to modulate the CO release property and solubility.

Embodiments of the invention disclosed herein generally include methods and / or devices for increasing blood flow, controlling the vasodilatation of a patient's vascular structure, regulating the temperature of a portion of a mammal, and for improving various interventional procedures and / or therapeutic techniques. The device may also include one or more access ports, or apertures, that allow access to portions of the mammal's extremity to allow interventional type medical devices, therapeutic devices, surgical support equipment or patient monitoring devices to have access to the extremity on which a body element is disposed. The device may also be configured to allow other supporting components, which may include IV or other catheters, a means of accessing to a portion of the extremity positioned inside the temperature regulating device. In one configuration the device comprises flexible materials that are adapted to conform to the surface of the extremity disposed in the device when a vacuum pressure is applied to an internal region of the device.

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

The specification discloses purine nucleotide analogues which modulate cardiac muscle contractility and possess vasodilator activity. In addition, related methods of administration and the identity of receptors that bind these compounds are disclosed.

The present invention is directed to using a thermoregulatory sensor in conjunction with a cooling-normothermic-heating device that applies a desired thermal energy to a target heat exchange surface of a mammal that is under negative pressure. The thermoregulatory sensor, unlike the prior art, does not initiate and / or control the thermal energy applied to the mammal. Instead the thermoregulatory sensor initiates, controls and / or manages the negative pressure applied to the target heat exchange surface. By initiating, controlling and / or managing the negative pressure, (1) the vasodilation of the target heat exchange surface is also controlled and / or managed and / or (2) thermal communion between the exchange surfaces (skin and heat exchanger) is controlled, and / or managed.

A “relaxoscope” (100) detects the degree of arterial endothelial function. Impairment of arterial endothelial function is an early event in atherosclerosis and correlates with the major risk factors for cardiovascular disease. An artery (115), such as the brachial artery (BA) is measured for diameter before and after several minutes of either vasoconstriction or vasorelaxafion. The change in arterial diameter is a measure of flow-mediated vasomodification (FMVM). The relaxoscope induces an artificial pulse (128) at a superficial radial artery (115) via a linear actuator (120). An ultrasonic Doppler stethoscope (130) detects this pulse 10-20 cm proximal to the point of pulse induction (125). The delay between pulse application and detection provides the pulse transit time (PTT). By measuring PTT before (160) and after arterial diameter change (170), FMVM may be measured based on the changes in PTT caused by changes in vessel caliber, smooth muscle tone and wall thickness.

A method for stimulating perfusion and minimizing postischemic reperfusion injury. A patient is selected having compromised perfusion in a tissue or in the microcirculation of an organ. An ultrasound transducer is applied to a location near the tissue. The transducer is activated to initiate exposure of the tissue to ultrasound at a frequency of 100 KHz to 2.5 MHz for 0.5 to 15 minutes duration, wherein local vasodilatation is stimulated. In certain cases, the methods further include a step of confirming that local vasodilatation is stimulated by measuring enhancement in perfusion. Ultrasound devices are also described for carrying out the methods. The devices and methods can be used to enhance myocardial perfusion, cerebral perfusion, and perfusion of transplanted tissues.

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and / or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and / or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and / or acid, or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic; aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.

Metal carbonyls are used in combination with at least one guanylate cyclase stimulant / stabilizer to deliver CO having biological activity, for example vasodilatation and inhibition of platelet aggregation. The two components may be administered simultaneously or sequentially. A particular described combination is tricarbonylchloro(glycinato)ruthenium(II) and the drug YC-1.

A negative pressure, thermal energy device has an enclosure that receives a patient's body part. The body part is positioned in the enclosure and contacts a thermal energy contacting surface. The thermal energy contacting surface transfers its thermal energy to the body part. While in the enclosure, the body part is also exposed to a negative pressure to cause vasodilation. The combination of the vasodilation and the thermal energy transfer alter the patient's body core temperature. To ensure the body part remains in contact with the thermal contacting surface, the enclosure has a portion thereof that moves when negative pressure is in the enclosure. When the negative pressure is applied, the deforming enclosure material is pulled toward the body part to provide a positive pressure on the body part that ensures the body part effectively contacts the thermal energy contacting surface.

Oligomers of L-arginine may be used to provide prophylactic or therapeutic cosmetic or other enhancements to keratinous tissues such as skin, hair, lips and gums through vasodilation. Topical compositions preferably comprise (a) an enhancing effective amount of an oligomer having from 7 to 15 subunits, each subunit consisting of a member of the group selected from L-arginine and physiologically acceptable salts of L-arginine that enhance vasodilation through production of nitric oxide, and (b) a cosmetically or dermatologically acceptable vehicle.

The invention discloses a magnetic resonance angiography method. The magnetic resonance angiography method includes applying a flowing sensitive dispersed phase gradient magnetic field in the readout direction and / or the phase encoding direction and / or the layer selection direction in a vasoconstriction period and then applying a residual magnetic moment removing gradient magnetic field after the flowing sensitive dispersed phase gradient magnetic field is applied; collecting blood flow images in the vasoconstriction period; collecting blood flow images in a vasodilatation period; and carrying out subtraction on the blood flow images in the vasoconstriction period and the blood flow images in the vasodilatation period to obtain blood flow images. The invention further discloses a magnetic resonance angiography system. According to the magnetic resonance angiography method and the magnetic resonance angiography system, in the specific implementation method, the flowing sensitive dispersed phase is used in the vasoconstriction period imaging process, so that intra-arterial self-spin dispersed phase can significantly lower arterial blood signals, and therefore the influence on imaging due to the velocity and the direction of blood flow can be reduced, high-quality peripheral arterial images can be obtained, and clinical practicability of the non-enhanced magnetic resonance angiography technology is improved.

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising:wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, against agonist pro-angiogenic, pro-permeability, vasodilatory isoforms of VEGF. Disclosed antibodies and antibody fragments are characterized by being capable of binding to and neutralizing pro-angiogenic forms of VEGF while not effecting isoforms of VEGF which are anti angiogenic. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

The present invention relates to a pad for treating skin diseases, comprising agar gel and a fiber layer fixed to the inside of the gel, and a manufacturing method therefor. The pad of the present invention inhibits blood vessel exudation symptoms according to vasodilation by maintaining a low temperature of the affected area, reduces an itchy sensation and, at the same time, removes, from the skin, plasma proteins and various plasma-derived substances accumulated in skin tissue, thereby having an effect of alleviating the symptoms of the affected area.

Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and / or promote neuroregeneration.

The present invention is a powerful vasodilatation and transdermal penetration system, which quickly penetrates the dermis of the skin and deposits beneficial ingredients at the subcutaneous layer, which then stimulates the capillary blood flow to fat cells and increases the metabolizing process of fat cells and cellulite, thereby reducing the size of fat cells, thus creating a smoother appearance to the surface of the skin as well as reducing the appearance of the size of the affected area.

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.

The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.

Apparatus and methods are provided for treating a human condition by providing an appendage chamber having a thermal exchange member. A vacuum may be applied to the appendage chamber to maintain vasodilation of an appendage when placed within the appendage chamber. The appendage may be heated or cooled at the thermal exchange member for therapeutic application of thermal energy to treat a number of circulatory, neurological, lymphatic, or endocrinal maladies.

A system for providing an early risk recognition monitoring by measurement of a peripheral tissue perfusion of a patient instead of clinically significant changes in systemic blood pressure and / or blood flow comprises a wristband device for gathering measurement data of the patient. The device measures a first temperature (t1) of the patient at the first wrist (or distal antebrachium) point and a second temperature (t2) of the patient at the second finger point, whereupon the system determines altered peripheral tissue perfusion by determining temperature gradient (Δt) between said first and second points. If the gradient (Δt) exceeds or deceeds a predetermined range, the system construes the exceeding as a peripheral vasoconstriction and the deceeding as a peripheral vasodilatation, and thereby provides a first early risk recognition phase (p1) and transmits it as a warning indication to end devices of health care personnel.